Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies.
Although thymic epithelial tumors (TETs) are rare in the general population, they represent the most frequently diagnosed primary malignant tumor of the anterior mediastinum. Unlike localized disease, metastatic disease is invariably fatal. While several chemotherapy agents have proven to be effective in TETs, somatostatin analogs are the only targeted agents with an established role in this disease. Everolimus is an mTOR inhibitor with multiple application in oncology. In this report, we show for the first time that everolimus was effective in two heavily pretreated patients with advanced TETs, with a progression-free survival longer than 1 year and minimal toxicity.
Clinical Endocrinology and Oncology Department, UniversityFederico II, Via Pansini 5, 80128 Naples,Italy. giovpalm@unina.it
Giovannella
G
Palmieri
Carlo
C
Buonerba
Piera
P
Federico
Luigi
L
Formisano
Lucia
L
Nappi
Giuseppe
G
Di Lorenzo
Mirella
M
Marino
Vincenzo
V
Damiano